The teacher unions may be the most destructive lobby in America, but the AARP isn’t far behind.
As we have previously reported, AARP, UnitedHealth, and the Democratic Party have built a juggernaut alliance – UnitedHealth sells about $20 billion per year in AARP branded insurance products, AARP takes in a cool billion from its 5% skim, and one way or another a hefty chunk of it ends up supporting Democratic candidates and policies that benefit UnitedHealth and keep the merry-go-round in motion.
But now the story of AARP’s nefarious activities gets worse. The Daily Caller reports:
AARP spent more than $60 million between 2019 and summer 2022 advocating for a provision that eventually made it into the IRA allowing Medicare to negotiate with pharmaceutical companies over the prices of certain drugs, according to an article posted on the group’s website. The provisions would require the Department of Health and Human Services (HHS) to negotiate the prices of certain drugs with drug manufacturers starting in 2026.
“We agreed that state directors would drop everything and get on this. Calls started going in to the White House and congressional leaders by 10 a.m. We had never responded to something so quickly,” Nancy LeaMond, AARP executive vice president and chief advocacy and engagement officer, said in the article…
So it was a full-court press for drug price controls. What the AARP failed to divulge to its members is that one of the biggest beneficiaries of the Medicare negotiated price controls was United Health Group – AARP’s funder. These drug price controls have started to reduce private funding for new drug development for Parkinson’s, cancer, ALS, and other painful and deadly diseases that afflict AARP’s members.
But it seems clear that senior citizens’ interests come second when it comes to the pay-to-play operations at AARP.